The effect of duloxetine on primary pain symptoms in Parkinson disease

Clinical Neuropharmacology

Volumn 30, Issue 4, 2007, Pages 201-205

  Djaldetti, Ruth ^a   Yust Katz, Shlomit ^a   Kolianov, Vadim ^a   Melamed, Eldad ^a   Dabby, Ron ^b,c  

^a RABIN MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Duloxetine; Parkinson disease; Primary pain

Indexed keywords

DULOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MALE; MCGILL PAIN QUESTIONNAIRE; METHODOLOGY; NAUSEA AND VOMITING; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PARKINSON DISEASE; PARKINSON DISEASE QUALITY OF LIFE QUESTIONNAIRE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; SOMNOLENCE; TREATMENT DURATION; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VERTIGO; VISUAL ANALOG SCALE;

AGED; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PARKINSON DISEASE; QUALITY OF LIFE; THIOPHENES;

EID: 34548460736     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/wnf.0b013e3180340319     Document Type: Article

References (15)

1. Snider SR, Fahn S, Isgreen WP, et al. Primary sensory symptoms in parkinsonism. Neurology 1976;26: 423-429.
2. Ford B. Pain in Parkinson's disease. Clin Neurosci 1998;5:63-72.
3. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995;60:3-38.
4. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984;7:309-338.
5. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-118.
6. Arnold LM, Rosen A, Prtichett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;15:119. 5-15.
7. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51: 745-752.
8. Melzack R. The Short-form McGill Pain Questionnaire. Pain 1987;30:191-197.
9. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-138.
10. Beck AT, Steer RA, Ball R, et al. Comparison of Back Depression Inventories-IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588-597.
11. Djaldetti R, Shifrin A, Rogowski Z, et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004; 62:2171-2175.
12. Waseem S, Gwinn-Hardy K. Pain in Parkinson's disease. Common yet seldom recognized symptom is treatable. Postgrad Med 2001;110: 33-34. 39-40, 46.
13. Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004;62:S12-S17.
14. Kilts C. In vivo neuroimaging correlates of the efficacy of paroxetine in the treatment of mood and anxiety disorders. Psychopharmacol Bull 2003; 37(suppl 1):19-28.
15. Kugaya A, Sanacora G, Staley JK, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 2004;56:497-502.